International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 47

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in *Cumulative List No. 10, 2002* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 47

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la *Liste récapitulative No. 10, 2002* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 47

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran reunidas en *Cumulative List No. 10, 2002* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN *Chemical name or description; Molecular formula; Graphic formula*

DCI Recommandée *Nom chimique ou description; Formule brute; Formule développée*

DCI Recomendada *Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

acidum gadocoleticum

gadocoletic acid

trihydrogen [3β-[[(4*S*)-4-[bis[2-[bis[(carboxy-κ*O*)methyl]amino-κ*N*]ethyl]amino-κ*N*]-4-(carboxy-κ*O*)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]= gadolinate(3-)

acide gadocolétique

trihydrogéno[3β-[[(4*S*)-4-[bis[2-[bis[(carboxy-κ*O*)méthyl]amino-*N*]éthyl]amino-κ*N*]-4-(carboxy-κ*O*)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]= gadolinate(3-)

ácido gadocolético

trihidrógeno[3β-[[(4*S*)-4-[bis[2-[bis[(carboxi-κ*O*)metil]amino-κ*N*]etil]amino-κ*N*]-4-(carboxi-κ*O*)butanoil]amino]-12α-hidroxi-5β-colan-24-ato(6-)]gadolinato(3-)

$C_{41}H_{63}GdN_4O_{14}$



afeletecanum

afeletecan

camptothecin, ester with *N*-[[*p*-[(3-*O*-methyl-β-L-fucopyranosyl)oxy]phenyl]= thiocarbamoyl]-L-histidyl-L-valine

afélétécan

(2*S*)-2-[[(2*S*)-3-(1*H*-imidazol-4-yl)-2-[[[[4-[(3-*O*-méthyl-6-désoxy-β-L-galactopyranosyl)oxy]phényl]amino]thiocarbonyl]amino]propanoyl]amino]-3-méthylbutanoate de (4*S*)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yle

afeletecán

éster de la camptotecina con *N*-[[*p*-[(3-*O*-metil-β-L-fucopiranosil)oxi]fenil]= tiocarbamoil]-L-histidil-L-valina

$C_{45}H_{49}N_7O_{11}S$



alfimeprasum

alfimeprase — [3-L-serine]fibrolase-(3-203)-peptide (fibrolase : fibrinolytic enzyme isolated from *Agkistrodon contrix contrix* venom)

alfiméprase — [3-L-sérine]fibrolase-(3-203)-peptide (fibrolase : enzyme fibrinolytique extraite de venin d'*Agkistrodon contrix contrix*)

alfimeprasa — [3-L-serina]fibrolasa-(3-203)-péptido (fibrolasa : enzime fibrinolítica extraida de veneno de *Agkistrodon contrix contrix*)

$C_{985}H_{1541}N_{285}O_{301}S_{12}$

SFPQRYVQ LVIVADHRMN TKYNGDSDKI RQWVHQIVNT
INEIYRPLNI QFTLVGLEIW SNQDLITVTS VSHDTLASFG
NWRETDLLRR QRHDNAQLLT AIDFDGDTVG LAYVGGMCQL
KHSTGVIQDH SAINLLVALT MAHELGHNLG MNHDGNQCHC
GANSCVMAAM LSDQPSKLFS DCSKKDYQTF LTVNNPQCIL
NKP

alicaforsenum

alicaforsen

2'-deoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioadenylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioadenylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioadenylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioguanylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxyadenosine nonadecasodium salt

alicaforsen

2'-désoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioadénylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioadénylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioadénylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioguanylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxyadénosine nonadécasodique

alicaforseno

2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioadenilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioadenilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-(*R*)-*P*-tiotimidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioadenilil-(3'→5')-(*R*)-*P*-tiotimidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-(*R*)-*P*-tiotimidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxiadenosina nonadecasódica

$C_{192}H_{225}N_{75}Na_{19}O_{98}P_{19}S_{19}$

alilusemum

alilusem

7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4(1*H*)-one (*E*)-*O*-sulfooxime

alilusem

(*E*)-*O*-sulfooxime de 7-chloro-1-(2-méthylbenzoyl)-2,3-dihydroquinoléin-4(1*H*)-one

alilusem

(*E*)-*O*-sulfooxima de 7-cloro-1-(2-metilbenzoil)-2,3-dihidroquinolin-4(1*H*)-ona

$C_{17}H_{15}ClN_2O_5S$



ambrisentanum

ambrisentan (+)-(2*S*)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid

ambrisentan (+)-acide (2*S*)-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3-méthoxy-3,3-diphénylpropanoïque

ambrisentán (+)-ácido (2*S*)-2-[(4,6-dimetilpirimidin-2-il)oxi]-3-metoxi-3,3-difenilpropanoico

$C_{22}H_{22}N_2O_4$



amdoxovirum

amdoxovir [(2*R*,4*R*)-4-(2,6-diamino-9*H*-purin-9-yl)-1,3-dioxolan-2-yl]methanol

amdoxovir [(2*R*,4*R*)-4-(2,6-diamino-9*H*-purin-9-yl)-1,3-dioxolan-2-yl]méthanol

amdoxovir [(2*R*,4*R*)-4-(2,6-diamino-9*H*-purin-9-il)-1,3-dioxolan-2-il]metanol

$C_9H_{12}N_6O_3$



amelubantum

amelubant ethyl [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]benzyl]=oxy]phenyl](imino)methyl]carbamate

amélubant [[4-[[3-[[4-[1-(4-hydroxyphényl)-1-méthyléthyl]phénoxy]méthyl]benzyl]oxy]=phényl](imino)méthyl]carbamate d'éthyle

amelubant [[4-[[3-[[4-[1-(4-hidroxifenil)-1-metiletil]fenoxi]metil]bencil]oxi]fenil](imino)metil]=carbamato de etilo

$C_{33}H_{34}N_2O_5$



amotosalenum

amotosalen 3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7*H*-furo[3,2-*g*][1]benzopyran-7-one

amotosalène 3-[(2-aminoéthoxy)méthyl]-2,5,9-triméthyl-7*H*-furo[3,2-*g*][1]benzopyran-7-one

amotosaleno 3-[(2-aminoetoxi)metil]-2,5,9-trimetil-7*H*-furo[3,2-*g*][1]benzopiran-7-ona

$C_{17}H_{19}NO_4$



bimatoprostum

bimatoprost (*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihydroxy-2-[(1*E*,3*S*)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-*N*-ethyl-5-heptenamide

bimatoprost (*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihydroxy-2-[(1*E*,3*S*)-3-hydroxy-5-phénylpent-1-ényl]cyclopentyl]-*N*-éthylhept-5-énamide

bimatoprost (*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihidroxi-2-[(1*E*,3*S*)-3-hidroxi-5-fenilpent-1-enil]ciclopentil]-*N*-etilhept-5-enamida

$C_{25}H_{37}NO_4$



caldaretum

caldaret — 5-methyl-2-(piperazin-1-yl)benzenesulfonic acid

caldaret — acide 5-méthyl-2-(pipérazin-1-yl)benzènesulfonique

caldaret — ácido 5-metil-2-(piperazin-1-il)bencenosulfónico

$C_{11}H_{16}N_2O_3S$



cipralisantum

cipralisant — 4-[(1*R*,2*R*)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1*H*-imidazole

cipralisant — 4-[(1*R*,2*R*)-2-(5,5-diméthylhex-1-ynyl)cyclopropyl]-1*H*-imidazole

cipralisant — 4-[(1*R*,2*R*)-2-(5,5-dimetilhex-1-inil)ciclopropil]-1*H*-imidazol

$C_{14}H_{20}N_2$



darbepoetinum alfa

darbepoetin alfa — [30-L-asparagine,32-L-thronine,87-L-valine,88-L-asparagine, 90-L-threonine]erythropoietin (human)

darbépoétine alfa — [30-L-asparagine,32-L-thréonine,87-L-valine,88-L-asparagine, 90-L-thréonine]érythropoiétine humaine

darbepoetina alfa — [30-L-asparagina,32-L-treonina,87-L-valina,88-L-asparagina, 90-L-treonina]eritropoietina humana

$C_{800}H_{1300}N_{228}O_{243}S_5$

APPRLICDSR VLERYLLEAK EAENITTGCN ETCSLNENIT
VPDTKVNFYA WKRMEVGQQA VEVWQGLALL SEAVLRGQAL
LVNSSQVNET LQLHVDKAVS GLRSLTTLLR ALGAQKEAIS
PPDAASAAPL RTITADTFRK LFRVYSNFLR GKLKLYTGEA
CRTGD

drotrecoginum alfa (activatum)

drotrecogin alfa (activated) — blood coagulation factor XIV (human)

drotrécogine alfa (activé) — facteur XIV humain de coagulation sanguine

drotrecogina alfa (activada) — factor XIV de coagulación sanguínea (humano)

$C_{2071}H_{3165}N_{581}O_{640}S_{31}$



ecalcidenum

ecalcidene — 1-[(5*Z*,7*E*,20*S*)-1α,3β-dihydroxy-9,10-secochola-5,7,10(19)-trien-24-oyl]piperidine

écalcidène — 1-[(5*Z*,7*E*,20*S*)-1α,3β-dihydroxy-9,10-sécochola-5,7,10(19)-trién-24-oyl]pipéridine

ecalcideno — 1-[(5*Z*,7*E*,20*S*)-1α,3β-dihidroxi-9,10-secocola-5,7,10(19)-trien-24-oil]piperidina

$C_{29}H_{45}NO_3$



efalizumabum

efalizumab — immunoglobulin G1, anti-(human antigen CD11a) (human-mouse monoclonal hu1124 γ1-chain), disulfide with human-mouse monoclonal hu1124 light chain, dimer

éfalizumab — immunoglobuline G1, anti-(antigène CD11a humain) (chaîne γ1 de l'anticorps monoclonal de souris humanisé hu1124),dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris humanisé hu1124

efalizumab — inmunoglobulina G1, anti-(antígeno CD11a humano) (cadena γ1 del anticuerpo monoclonal humanizado de ratón hu1124), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón hu1124

enfuvirtidum

enfuvirtide — acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L-α-glutamyl-L-α-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-asparaginyl-L-α-glutamyl-L-glutaminyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-leucyl-L-α-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phenylalaninamide

enfuvirtide — acétyl-L-tyrosyl-L-thréonyl-L-séryl-L-leucyl-L-isoleucyl-L-histidyl-L-séryl-L-leucyl-L-isoleucyl-L-α-glutamyl-L-α-glutamyl-L-séryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-asparaginyl-L-α-glutamyl-L-glutaminyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-leucyl-L-α-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-séryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phénylalaninamide

enfuvirtida — acetil-L-tirosil-L-treonil-L-seril-L-leucil-L-isoleucil-L-histidil-L-seril-L-leucil-L-isoleucil-L-α-glutamil-L-α-glutamil-L-seril-L-glutaminil-L-asparaginil-L-glutaminil-L-glutaminil-L-α-glutamil-L-lisil-L-asparaginil-L-α-glutamil-L-glutaminil-L-α-glutamil-L-leucil-L-leucil-L-α-glutamil-L-leucil-L-α-aspartil-L-lisil-L-triptofil-L-alanil-L-seril-L-leucil-L-triptofil-L-asparaginil-L-triptofil-L-fenilalaninamida

$C_{204}H_{301}N_{51}O_{64}$



epafipasum

epafipase — 2-acetyl-1-alkyl-*sn*-glycero-3-phosphocholine deacetylase-(6-400)-peptide (human)

épafipase — désacétylase-(6-400)-peptide (humaine) de la 2-acétyl-1-alkyl-*sn*-glycéro-3-phosphocholine

epafipasa — 1-*O*-alquil-2-acetil-*sn*-glicero-3-fosfocolina 6-400-desacetilasa (humana)

$C_{2016}H_{3107}N_{545}O_{586}S_{14}$

AAASFGQTKI PRGNGPYSVG CTDLMFDHTN KGTFLRLYYP
SQDNDRLDTL WIPNKEYFWG LSKFLGTHWL MGNILRLLFG
SMTTPANWNS PLRPGEKYPL VVFSHGLGAF RTLYSAIGID
LASHGFIVAA VEHRDRSASA TYYFKDQSAA EIGDKSWLYL
RTLKQEEETH IRNEQVRQRA KECSQALSLI LDIDHGKPVK
NALDLKFDME QLKDSIDREK IAVIGHSFGG ATVIQTLSED
QRFRCGIALD AWMFPLGDEV YSRIPQPLFF INSEYFQYPA
NIIKMKKCYS PDKERKMITI RGSVHQNFAD FTFATGKIIG
HMLKLKGDID SNVAIDLSNK ASLAFLQKHL GLHKDFDQWD
CLIEGDDENL IPGTNINTTN QHIMLQNSSG IEKYN

epoetinum delta

epoetin delta — 1-165-erythropoietin (human HMR4396), glycoform δ

époétine delta — 1-165-érythropoiétine (humaine HMR4396), glycoforme δ

epoetina delta — 1-165-eritropoietina (humana HMR4396), glicoforma δ

$C_{809}H_{1301}N_{229}O_{240}S_5$

APPRLICDSR VLERYLLEAK EAEN*ITTGCA EHCSLNEN*IT
VPDTKVNFYA WKRMEVGQQA VEVWQGLALL SEAVLRGQAL
LVN*SSQPWEP LQLHVDKAVS GLRSLTTLLR ALGAQKEAIS
PPDAAS*AAPL RTITADTFRK LFRVYSNFLR GKLKLYTGEA
CRTGD

* : glycosylation sites / sites de glycosylation / posiciones de glicosilación

erlotinibum

erlotinib *N*-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

erlotinib *N*-(3-éthynylphényl)-6,7-bis(2-méthoxyéthoxy)quinazolin-4-amine

erlotinib *N*-(3-etinilfenil)-6,7-bis(2-metoxietoxi)quinazolin-4-amina

$C_{22}H_{23}N_3O_4$



febuxostatum

febuxostat 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

fébuxostat acide 2-[3-cyano-4-(2-méthylpropoxy)phényl]-4-méthylthiazole-5-carboxylique

febuxostat ácido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxílico

$C_{16}H_{16}N_2O_3S$



feloprentanum

feloprentan (2*S*)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3,3-diphenylpropanoic acid

féloprentan acide (2*S*)-3-[2-(3,4-diméthoxyphényl)éthoxy]-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3,3-diphénylpropanoïque

feloprentán ácido (2*S*)-3-[2-(3,4-dimetoxifenil)etoxi]-2-[(4,6-dimetilpirimidin-2-il)oxi]-3,3-difenilpropanoico

$C_{31}H_{32}N_2O_6$



finafloxacinum

finafloxacin (-)-8-cyano-1-cyclopropyl-6-fluoro-7-[(4a*S*,7a*S*)-hexahydropyrrolo[3,4-*b*]-1,4-oxazin-6(2*H*)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

finafloxacine (-)-acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4a*S*,7a*S*)-hexahydropyrrolo[3,4-*b*]-1,4-oxazin-6(2*H*)-yl)-4-oxo-1,4-dihydroquinoléine-3-carboxylique

finafloxacino (-)-ácido 8-ciano-1-ciclopropil-6-fluoro-7-[(4a*S*,7a*S*)-hexahidropirrolo[3,4-*b*]-1,4-oxazin-6(2*H*)-il)-4-oxo-1,4-dihidroquinolina-3-carboxílico

$C_{20}H_{19}FN_4O_4$



gadomelitolum

gadomelitol hydrogen [2,2',2'',2'''-[1,4,7,10-tetraazacyclododecane-1,4,7,10-triyl]tetrakis=[5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2*S*,3*R*,4*R*,5*R*)-2,3,4,5,6-pentahydroxyhexyl-2,4,6-tribromo]carbamoyl]phenyl]amino]-2-oxoethyl]carbamoyl]phenyl]=carbamoyl]phenyl]amino]-2-oxoethyl]amino]-5-oxopentanoato](4-)]=gadolinate(1-)

gadomélitol hydrogéno-[2,2',2'',2'''-[1,4,7,10-tétraazacyclododécane-1,4,7,10-triyl]tétrakis[5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2*S*,3*R*,4*R*,5*R*)-2,3,4,5,6-pentahydroxyhexyl-2,4,6-tribromo]carbamoyl]phényl]amino]-2-oxoéthyl]carbamoyl]phényl]=carbamoyl]phényl]amino]-2-oxoéthyl]amino]-5-oxopentanoato](4-)]=gadolinate(1-)

gadomelitol

hidrógeno-[2,2',2'',2'''-[1,4,7,10-tetraazaciclododecano-1,4,7,10-triil]tetrakis=[5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2*S*,3*R*,4*R*,5*R*)-2,3,4,5,6-pentahidroxihexil-2,4,6-tribromo]carbamoil]fenil]amino]-2-oxoetil]carbamoil]fenil]carbamoil]fenil]=amino]-2-oxoetil]amino]-5-oxopentanoato](4-)]gadolinato(1-)

$C_{228}H_{313}Br_{12}GdN_{32}O_{116}$



garnocestimum

garnocestim

5-73-macrophage inflammatory protein 2α (human gene gro2)

garnocestim

CXC chimiokine GROβ-(5-73)-peptide (GROβ : protéine inflammatoire humaine sécrétée par les macrophages)

garnocestim

CXC quimiokina GROβ-(5-73)-péptido (GROβ : proteína inflamatoria humana secretada por los macrófagos)

$C_{325}H_{557}N_{97}O_{95}S_6$



gefitinibum

gefitinib

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine

géfitinib

N-(3-chloro-4-fluorophényl)-7-méthoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine

gefitinib

N-(3-cloro-4-fluorofenil)-7-metoxi-6-[3-(morfolin-4-il)propoxi]quinazolin-4-amina

$C_{22}H_{24}ClFN_4O_3$



ingliforibum

ingliforib — 5-chloro-*N*-[(1*S*,2*R*)-1-benzyl-3-(*cis*-3,4-dihydroxypyrrolidin-1-yl)-2-hydroxy-3-oxopropyl]-1*H*-indole-2-carboxamide

ingliforib — 5-chloro-*N*-[(1*S*,2*R*)-1-benzyl-3-(*cis*-3,4-dihydroxypyrrolidin-1-yl)-2-hydroxy-3-oxopropyl]-1*H*-indole-2-carboxamide

ingliforib — 5-cloro-*N*-[(1*S*,2*R*)-1-bencil-3-(*cis*-3,4-dihidroxipirrolidin-1-il)-2-hidroxi-3-oxopropil]-1*H*-indol-2-carboxamida

$C_{23}H_{24}ClN_3O_5$



ipravacainum

ipravacaine — (2*RS*)-1-(cyclopropylmethyl)-2',6'-dimethyl-2-piperidinecarboxanilide

ipravacaïne — (2*RS*)-1-(cyclopropylméthyl)-*N*-(2,6-diméthylphényl)pipéridine-2-carboxamide

ipravacaína — (2*RS*)-1-(ciclopropilmetil)-*N*-(2,6-dimetilfenil)piperidina-2-carboxamida

$C_{18}H_{26}N_2O$



and enantiomer
et énantiomère
y enantiómero

iseganánum

iseganan — L-arginylglycylglycyl-L-leucyl-L-cysteinyl-L-tyrosyl-L-cysteinyl-L-arginylglycyl-L-arginyl-L-phenylalanyl-L-cysteinyl-L-valyl-L-cysteinyl-L-valylglycyl-L-argininamide cyclic (5→14),(7→12)-bis(disulfide)

iséganan — (5→14),(7→12)-bis(disulfure cyclique) de L-arginyl-glycyl-glycyl-L-leucyl-L-cystéinyl-L-tyrosyl-L-cystéinyl-L-arginyl-glycyl-L-arginyl-L-phénylalanyl-L-cystéinyl-L-valyl-L-cystéinyl-L-valyl-glycyl-L-argininamide

iseganán — (5→14),(7→12)-bis(disulfuro cíclico) de L-arginil-glicil-glicil-L-leucil-L-cisteinil-L-tirosil-L-cisteinil-L-arginil-glicil-L-arginil-L-fenilalanil-L-cisteinil-L-valil-L-cisteinil-L-valil-glicil-L-argininamida

$C_{78}H_{126}N_{30}O_{18}S_4$



labetuzumabum

labetuzumab — immunoglobulin G, anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 γ-chain), disulfide with human-mouse monoclonal hMN-14 κ-chain, dimer

labétuzumab — immunoglobuline G, anti-(antigène carcinoembryonnaire humain) (chaîne-γ de l'anticorps monoclonal de souris humanisé hMN-14), dimère du disulfure avec la chaîne-κ de l'anticorps monoclonal de souris humanisé hMN-14

labetuzumab — inmunoglobulina G, anti-(antígeno carcinoembrionario humano) (cadena-γ del anticuerpo monoclonal humanizado de ratón hMN-14), dímero del disulfuro con la cadena-κ del anticuerpo monoclonal humanizado de ratón hMN-14

laniquidarum

laniquidar — methyl 6,11-dihydro-11-[1-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-*b*][3]benzazepine-3-carboxylate

laniquidar — 11-[1-[2-[4-(quinoléin-2-ylméthoxy)phényl]éthyl]pipéridin-4-ylidène]-6,11-dihydro-5*H*-imidazo[2,1-*b*][3]benzazépine-3-carboxylate de méthyle

laniquidar — 11-[1-[2-[4-(quinolin-2-ilmetoxi)fenil]etil]piperidin-4-ilideno]-6,11-dihidro-5*H*-imidazo[2,1-*b*][3]benzazepina-3-carboxilato de metilo

$C_{37}H_{36}N_4O_3$



lapisteridum

lapisteride *N*-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide

lapistéride *N*-[1-(4-méthoxyphényl)-1-méthyléthyl]-3-oxo-4-aza-5α-androst-1-ène-17β-carboxamide

lapisterida *N*-[1-(4-metoxifenil)-1-metiletil]-3-oxo-4-aza-5α-androst-1-eno-17β-carboxamida

$C_{29}H_{40}N_2O_3$



laquinimodum

laquinimod 5-chloro-*N*-ethyl-4-hydroxy-1-methyl-2-oxo-*N*-phenyl-1,2-dihydroquinoline-3-carboxamide

laquinimod 5-chloro-*N*-éthyl-4-hydroxy-1-méthyl-2-oxo-*N*-phényl-1,2-dihydroquinoléine-3-carboxamide

laquinimod 5-cloro-*N*-etil-4-hidroxi-1-metil-2-oxo-*N*-fenil-1,2-dihidroquinolina-3-carboxamida

$C_{19}H_{17}ClN_2O_3$



laronidasum

laronidase	8-L-histidine-α-L-iduronidase (human)
laronidase	[8-L-histidine]-α-L-iduronidase humaine
laronidasa	8-L-histidina-α-L-iduronidasa (humana)

$C_{3169}H_{4854}N_{901}O_{884}S_{12}$

AEAPHLVHVD AARALWPLRR FWRSTGFCPP LPHSQADQYV
LSWDQQLNLA YVGAVPHRGI KQVRTHWLLE LVTTRGSTGR
GLSYNFTHLD GYLDLLRENQ LLPGFELMGS ASGHFTDFED
KQQVFEWKDL VSSLARRYIG RYGLAHVSKW NFETWNEPDH
HDFDNVSMTM QGFLNYYDAC SEGLRAASPA LRLGGPGDSF
HTPPRSPLSW GLLRHCHDGT NFFTGEAGVR LDYISLHRKG
ARSSISILEQ EKVVAQQIRQ LFPKFADTPI YNDEADPLVG
WSLPQPWRAD VTYAAMVVKV IAQHQNLLLA NTTSAFPYAL
LSNDNAFLSY HPHPFAQRTL TARFQVNNTR PPHVQLLRKP
VLTAMGLLAL LDEEQLWAEV SQAGTVLDSN HTVGVLASAH
RPQGPADAWR AAVLIYASDD TRAHPNRSVA VTLRLRGVPP
GPGLVYVTRY LDNGLCSPDG EWRRLGRPVF PTAEQFRRMR
AAEDPVAAAP RPLPAGGRLT LRPALRLPSL LLVHVCARPE
KPPGQVTRLR ALPLTQGQLV LVWSDEHVGS KCLWTYEIQF
SQDGKAYTPV SRKPSTFNLF VFSPDTGAVS GSYRVRALDY
WARPGPFSDP VPYLEVPVPR GPPSPGNP

* : glycosylation sites / sites de glycosylation / posiciones de glicosilación

⤷ : disulfide / disulfure / disulfuro

lirimilastum

lirimilast — 2-(2,4-dichlorobenzoyl)-3-ureidobenzofuran-6-yl methanesulfonate

lirimilast — méthanesulfonate de 2-(2,4-dichlorobenzoyl)-3-uréidobenzofuran-6-yle

lirimilast — metanosulfonato de 2-(2,4-diclorobenzoil)-3-ureidobenzofuran-6-ilo

$C_{17}H_{12}Cl_2N_2O_6S$



livaraparinum calcium

livaraparin calcium — calcium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 6-*O*-sulfo-structure at the reducing end of their chain; the mass-average molecular mass ranges between 3000 and 5000 with 75% is less than 8000; the degree of sulfatation is approximately 2 per disaccharidic unit

livaraparine calcique — sel calcique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'acide nitreux, d'héparine de muqueuse intestinale de porc ; la majorité des composants de la livaraparine calcique possèdent une structure acide 2-*O*-sulfo-α-L-idopyranosuronique à l'extrémité non réductrice de leur chaîne et une structure 6-*O*-sulfatée à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative moyenne est de 3000 à 5000, 75% étant inférieur à 8000 ; le degré de sulfatation par unité disaccharide est voisin de 2

livaraparina cálcica — sal cálcica de una heparina de baja masa molecular obtenida de heparina de mucosa intestinal de cerdo por despolimerización con ácido nitroso; la mayoría de los componentes de la livaraparina cálcica tienen ácido 2-*O*-sulfo-α-L-idopiranosurónico en el extremo no reductor de la cadena y una estructura 6-*O*-sulfatada en el extremo reductor de la cadena; la masa molecular relativa media es de 3000 a 5000, siendo el 75% inferior a 8000; el grado de sulfatación por unidad de disacárido es aproximadamente 2

manifaxinum

manifaxine — (2*S*,3*S*,5*R*)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol

manifaxine — (2*S*,3*S*,5*R*)-2-(3,5-difluorophényl)-3,5-diméthylmorpholin-2-ol

manifaxina — (2*S*,3*S*,5*R*)-2-(3,5-difluorofenil)-3,5-dimetilmorfolin-2-ol

$C_{12}H_{15}F_2NO_2$



miglustatum

miglustat (2*R*,3*R*,4*R*,5*S*)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

miglustat (2*R*,3*R*,4*R*,5*S*)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol

miglustat (2*R*,3*R*,4*R*,5*S*)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol

$C_{10}H_{21}NO_4$



miriplatinum

miriplatin (*SP*-4-2)-[(1*R*,2*R*)-cyclohexane-1,2-diamine-*N*,*N'*]= bis(tetradecanoato-*O*)platinum

miriplatine (*SP*-4-2)-[(1*R*,2*R*)-cyclohexane-1,2-diamine-*N*,*N'*]= bis(tétradécanoato-*O*)platine

miriplatino (*SP*-4-2)-[(1*R*,2*R*)-ciclohexano-1,2-diamina-*N*,*N'*]= bis(tetradecanoato-*O*)platino

$C_{34}H_{68}N_2O_4Pt$



mirostipenum

mirostipen — [23-methionine]human myeloid progenitor inhibitory factor 1-(23-99)-peptide

mirostipen — [23-méthionine]facteur 1 d'inhibition du précurseur myéloïde humain-(23-99)-peptide

mirostipeno — [23-metionina]-(23-99)-péptido del factor 1 de inhibición del progenitor mieloide humano

$C_{380}H_{614}N_{112}O_{113}S_9$



mureletecanum

mureletecan — poly[[*N*-(2-hydroxypropyl)methacrylamide]-*co*-[camptothecin ester with *N*-[6-(2-methacrylamidoacetamido)hexanoyl]glycine]-*co*-[*N*-[[(2-hydroxypropyl)carbamoyl]methyl]methacrylamide]]

murélétécan — copolymère de *N*-[(2*RS*)-2-hydroxypropyl]-2-méthylpropénamide, de *N*-[2-[[6-[[2-[[(4*S*)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yl]oxy]-2-oxoéthyl]amino]-6-oxohexyl]amino]-2-oxoéthyl]-2-méthylpropénamide et de *N*-[2-[[(2*RS*)-2-hydroxypropyl]amino]-2-oxoéthyl]-2-méthylpropénamide

mureletecán — poli[[*N*-(2-hidroxipropil)metacrilamida]-*co*-[éster de camptotecina con *N*-[6-(2-metacrilamidoacetamido)hexanoil]glicina]-*co*-[*N*-[[(2-hidroxipropil)carbamoil]metil]metacrilamida]]



nasaruplasum beta

nasaruplase beta — prourokinase (enzyme-activating) human (clone pUK4/pUK18 protein moiety), glycosylated (murine cell line SP2/0)

nasaruplase bêta — prourokinase (activateur d'enzyme) humaine glycosylée dont le gène est cloné dans le vecteur pUK4/pUK18 et exprimée dans la lignée cellulaire murine SP2/0

nasaruplasa beta — prourokinasa (activador de enzima) humana glicosilada cuyo gen se clona en el vector pUK4/pUK18 y se expresa en la línea celular murina SP2/0

$C_{2031}H_{3121}N_{585}O_{601}S_{31}$



* : glycosylation sites / sites de glycosylation / posiciones de glicosilación

netoglitazonum

netoglitazone — (5*RS*)-5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]thiazolidine-2,4-dione

nétoglitazone — (5*RS*)-5-[[6-[(2-fluorophényl)méthoxy]naphtalén-2-yl]méthyl]thiazolidine-2,4-dione

netoglitazona — (5*RS*)-5-[[6-[(2-fluorofenil)metoxi]naftalen-2-il]metil]tiazolidina-2,4-diona

$C_{21}H_{16}FNO_3S$



and enantiomer
et énantiomère
y enantiómero

ospemifenum

ospemifene — 2-[*p*-[(*Z*)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]ethanol

ospémifène — (*Z*)-2-[4-(4-chloro-1,2-diphénylbut-1-ényl)phénoxy]éthanol

ospemifeno — 2-[p-[(Z)-4-cloro-1,2-difenil-1-butenil]fenoxi]etanol

$C_{24}H_{23}ClO_2$



pegfilgrastimum

pegfilgrastim — *N*-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with α-methyl-ω-hydroxypoly(oxyethylene)

pegfilgrastim — *N*-(3-hydroxypropyl)méthionylfacteur de stimulation de colonie humain, 1-éther avec le α-méthyl-ω-hydroxypoly(oxyéthylène)

pegfilgrastim — *N*-(3-hidroxipropil)metionilfactor de estimulación de colonias humano, 1-éter con el α-metil-ω-hidroxipoli(oxietileno)

$C_{849}H_{1347}N_{223}O_{244}S_9,(C_2H_4O)_n$



TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK

LCHPEELVLL GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS

GLFLYQGLLQ ALEGISPELG PTLDTLQLDV ADFATTIWQQ

MEELGMAPAL QPTQGAMPAF ASAFQRRAGG VLVASHLQSF

LEVSYRVLRH LAQP

pexelizumabum

pexelizumab — immunoglobulin, anti-(human complement C5 α-chain) (human-mouse monoclonal 5G1.1-SC single chain)

pexélizumab — immunoglobuline, anti-(chaîne-α du complément C5 humain) (mono chaîne de l'anticorps monoclonal de souris humanisé 5G1.1-SC)

pexelizumab — inmunoglobulina, anti-(cadena-α del complemento C5 humano) (mono cadena del anticuerpo monoclonal humanizado de ratón 5G1.1-SC)

pralnacasanum

pralnacasan (1*S*,9*S*)-*N*-[(2*R*,3*S*)-2-ethoxy-5-oxotetrahydrofuran-3-yl]-9-[(isoquinolin-1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-*H*-pyridazino[1,2-*a*][1,2]=diazepine-1-carboxamide

pralnacasan (1*S*,9*S*)-*N*-[(2*R*,3*S*)-2-éthoxy-5-oxotétrahydrofuran-3-yl]-9-[(isoquinoléin-1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-*H*-pyridazino[1,2-*a*]=[1,2]diazépine-1-carboxamide

pralnacasán (1*S*,9*S*)-*N*-[(2*R*,3*S*)-2-etoxi-5-oxotetrahidrofuran-3-il]-9-[(isoquinolin-1-ilcarbonil)amino]-6,10-dioxooctahidro-6-*H*-piridazino[1,2-*a*][1,2]diazepina-1-carboxamida

$C_{26}H_{29}N_5O_7$



pratosartanum

pratosartan 2-propyl-3-[[2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl]methyl]-5,6,7,8-tetrahydrocycloheptaimidazol-4(3*H*)-one

pratosartan 2-propyl-3-[[2'-(1*H*-tétrazol-5-yl)biphényl-4-yl]méthyl]-5,6,7,8-tétrahydrocycloheptaimidazol-4(3*H*)-one

pratosartán 2-propil-3-[[2'-(1*H*-tetrazol-5-il)bifenil-4-il]metil]-5,6,7,8-tetrahidrociclohepta imidazol-4(3*H*)-ona

$C_{25}H_{26}N_6O$



ragaglitazarum

ragaglitazar (-)-(2*S*)-2-ethoxy-3-[4-[2-(10*H*-phenoxazin-10-yl)ethoxy]phenyl]propanoic acid

ragaglitazar (-)-acide (2*S*)-2-éthoxy-3-[4-[2-(10*H*-phénoxazin-10-yl)éthoxy]phényl]=propanoïque

ragaglitazar (-)-ácido (2*S*)-2-etoxi-3-[4-[2-(10*H*-fenoxazin-10-il)etoxi]fenil]propanoico

$C_{25}H_{25}NO_5$



reslizumabum

reslizumab	immunoglobulin G4, anti-(human interleukin 5) (human-rat monoclonal SCH 55700 γ4-chain), disulfide with human-rat monoclonal SCH 55700 light chain, dimer
reslizumab	immunoglobuline G4, anti-(interleukine 5 humaine), (chaîne γ4 de l'anticorps monoclonal de rat humanisé SCH 55700), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de rat humanisé SCH 55700
reslizumab	immunoglobulina G4, anti-(interleukina 5 humana), (cadena γ4 del anticuerpo monoclonal humanizado de rata SCH 55700), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de rata SCH 55700

ruboxistaurinum

ruboxistaurin	(9*S*)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9*H*,19*H*-5,21:12,17-dimethenodibenzo[*e*,*k*]pyrrolo[3,4-*h*][1,4,13]oxadiazacyclohexadecene-18,20-dione
ruboxistaurine	(9*S*)-9-[(diméthylamino)méthyl]-6,7,10,11-tétrahydro-9*H*,19*H*-5,21:12,17-diméthénodibenzo[*e*,*k*]pyrrolo[3,4-*h*][1,4,13]oxadiazacyclohexadécène-18,20-dione
ruboxistaurina	(9*S*)-9-[(dimetilamino)metil]-6,7,10,11-tetrahidro-9*H*,19*H*-5,21:12,17-dimetenodibenzo[*e*,*k*]pirrolo[3,4-*h*][1,4,13]oxadiazaciclohexadeceno-18,20-diona

$C_{28}H_{28}N_4O_3$



semaxanibum

semaxanib — 3-[(*Z*)-(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone

sémaxanib — (*Z*)-3-[(3,5-diméthyl-1*H*-pyrrol-2-yl)méthylène]-1,3-dihydro-2*H*-indol-2-one

semaxanib — 3-[(*Z*)-(3,5-dimetilpirrol-2-il)metileno]-2-indolinona

$C_{15}H_{14}N_2O$



senazodanum

senazodan — 6-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydropyridazin-3(2*H*)-one

sénazodan — 6-[4-(pyridin-4-ylamino)phényl]-4,5-dihydropyridazin-3(2*H*)-one

senazodán — 6-[4-(piridin-4-ilamino)fenil]-4,5-dihidropiridazin-3(2*H*)-ona

$C_{15}H_{14}N_4O$



silodosinum

silodosin — (-)-1-(3-hydroxypropyl)-5-[(2*R*)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]=ethyl]amino]propyl]-2,3-dihydro-1*H*-indole-7-carboxamide

silodosine — (-)-1-(3-hydroxypropyl)-5-[(2*R*)-2-[[2-[2-(2,2,2-trifluoroéthoxy)phénoxy]=éthyl]amino]propyl]-2,3-dihydro-1*H*-indole-7-carboxamide

silodosina — (-)-1-(3-hidroxipropil)-5-[(2*R*)-2-[[2-[2-(2,2,2-trifluoroetoxi)fenoxi]etil]=amino]propil]-2,3-dihidro-1*H*-indol-7-carboxamida

$C_{25}H_{32}F_3N_3O_4$



solifenacinum

solifenacin (3*R*)-1-azabicyclo[2.2.2]oct-3-yl (1*S*)-1-phenyl-3,4-dihydroisoquinoline-2(1*H*)-carboxylate

solifénacine (1*S*)-1-phényl-3,4-dihydroisoquinoléine-2(1*H*)-carboxylate de (3*R*)-1-azabicyclo[2.2.2]oct-3-yle

solifenacina (1*S*)-1-fenil-3,4-dihidroisoquinolina-2(1*H*)-carboxilato de (3*R*)-1-azabiciclo[2.2.2]oct-3-ilo

$C_{23}H_{26}N_2O_2$



tadalafilum

tadalafil (6*R*,12a*R*)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-*b*]indole-1,4-dione

tadalafil (6*R*,12a*R*)-6-(1,3-benzodioxol-5-yl)-2-méthyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-*b*]indole-1,4-dione

tadalafilo (6*R*,12a*R*)-6-(1,3-benzodioxol-5-il)-2-metil-2,3,6,7,12,12a-hexahidropirazino[1',2':1,6]pirido[3,4-*b*]indol-1,4-diona

$C_{22}H_{19}N_3O_4$



tafluposidum

tafluposide 4-[(5*R*,5a*R*,8a*R*,9*S*)-9-[[4,6-*O*-[(1*R*)-ethylidene]-2,3-bis*O*-[(pentafluorophenoxy)acetyl]-β-D-glucopyranosyl]oxy]-6-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-*d*]-1,3-dioxol-5-yl]-2,6-dimethoxyphenyle dihydrogen phosphate

tafluposide dihydrogénophosphate de 4-[(5*R*,5a*R*,8a*R*,9*S*)-9-[[4,6-*O*-[(1*R*)-éthylidène]-2,3-bis*O*-[(pentafluorophénoxy)acétyl]-β-D-glucopyranosyl]oxy]-6-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphto[2,3-*d*]-1,3-dioxol-5-yl]-2,6-diméthoxyphényle

taflupósido dihidrógenofosfato de 4-[(5*R*,5a*R*,8a*R*,9*S*)-9-[[4,6-*O*-[(1*R*)-etilideno]-2,3-bis*O*-[(pentafluorofenoxi)acetil]-β-D-glucopiranosil]oxi]-6-oxo-5,5a,6,8,8a,9-hexahidrofuro[3',4':6,7]nafto[2,3-*d*]-1,3-dioxol-5-il]-2,6-dimetoxifenilo

$C_{45}H_{35}F_{10}O_{20}P$



telberminum

telbermin — vascular endothelial growth factor (human), dimer

telbermine — facteur de croissance de l'endothélium vasculaire humain (dimère)

telbermina — factor de crecimiento del endotelio vascular (humano), dímero

$C_{1612}H_{2536}N_{500}O_{498}S_{44}$



tenivastatinum

tenivastatin — (3*R*,5*R*)-7-[(1*S*,2*S*,6*R*,8*S*,8a*R*)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphtalen-1-yl]-3,5-dihydroxyheptanoic acid

ténivastatine — acide (3*R*,5*R*)-7-[(1*S*,2*S*,6*R*,8*S*,8a*R*)-8-[(2,2-diméthylbutanoyl)oxy]-2,6-diméthyl-1,2,6,7,8,8a-hexahydronaphtalén-1-yl]-3,5-dihydroxyheptanoïque

tenivastatina — ácido (3*R*,5*R*)-7-[(1*S*,2*S*,6*R*,8*S*,8a*R*)-8-[(2,2-dimetilbutanoil)oxi]-2,6-dimetil-1,2,6,7,8,8a-hexahidronaftalen-1-il]-3,5-dihidroxiheptanoico

$C_{25}H_{40}O_6$



tesaglitazarum

tesaglitazar	(2*S*)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]= propanoic acid
tésaglitazar	acide (2*S*)-2-éthoxy-3-[4-[2-[4-[(méthylsulfonyl)oxy]phényl]éthoxy]phényl]= propanoïque
tesaglitazar	ácido (2*S*)-2-etoxi-3-[4-[2-[4-[(metilsulfonil)oxi]fenil]etoxi]fenil]propanoico

$C_{20}H_{24}O_7S$



tofimilastum

tofimilast	9-cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine
tofimilast	9-cyclopentyl-7-éthyl-3-(thiophén-2-yl)-6,9-dihydro-5*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]pyridine
tofimilast	9-ciclopentil-7-etil-3-(tiofen-2-il)-6,9-dihidro-5*H*-pirazolo[3,4-*c*]-1,2,4-triazolo[4,3-*a*]piridina

$C_{18}H_{21}N_5S$



xidecaflurum

xidecaflur — 2,2-[(9*Z*)-9-octadecenylimino]diethanol hydrofluoride

xidécaflur — fluorhydrate de 2,2'-[(9*Z*)-octadec-9-énylimino]diéthanol

xidecaflur — hidrofluoruro de 2,2 -[(9*Z*)-9-octadecenilimino]dietanol

$C_{22}H_{46}FNO_2$



zanapezilum

zanapezil — 3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1*H*-1-benzazepin-8-yl)propan-1-one

zanapézil — 3-(1-benzylpipéridin-4-yl)-1-(2,3,4,5-tétrahydro-1*H*-1-benzazépin-8-yl)propan-1-one

zanapezilo — 3-(1-bencilpiperidin-4-il)-1-(2,3,4,5-tetrahidro-1*H*-1-benzazepin-8-il)propan-1-ona

$C_{25}H_{32}N_2O$



zonampanelum

zonampanel — [7-(1*H*-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2*H*)-yl]acetic acid

zonampanel — acide [7-(1*H*-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2*H*)-yl]acétique

zonampanel — ácido [7-(1*H*-imidazol-1-il)-6-nitro-2,3-dioxo-3,4-dihidroquinoxalin-1(2*H*)-il]acético

$C_{13}H_9N_5O_6$



zoniporidum

zoniporide *N*-carbamimidoyl-5-cyclopropyl-1-(quinolin-5-yl)-1*H*-pyrazole-4-carboxamide

zoniporide *N*-carbamimidoyl-5-cyclopropyl-1-(quinoléin-5-yl)-1*H*-pyrazole-4-carboxamide

zoniporida *N*-carbamimidoil-5-ciclopropil-1-(quinolin-5-il)-1*H*-pyrazol-4-carboxamida

$C_{17}H_{16}N_6O$



zoticasonum

zoticasone *S*-[(3*R*)-2-oxotetrahydrofuran-3-yl] 6α,9-difluoro-12β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate

zoticasone 6α,9-difluoro-12β,17-dihydroxy-16α-méthyl-3-oxoandrosta-1,4-diène-17β-carbothioate de *S*-[(3*R*)-2-oxotétrahydrofuran-3-yle]

zoticasona 6α,9-difluoro-12β,17-dihidroxi-16α-metil-3-oxoandrosta-1,4-dieno-17β-carbotioato de *S*-[(3*R*)-2-oxotetrahidrofuran-3-ilo]

$C_{25}H_{30}F_2O_6S$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Proposed International Nonproprietary Names (Prop. INN): List 59
Dénominations communes internationales proposées (DCI Prop.): Liste 59
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 59
(WHO Drug Information/Informations pharmaceutiques OMS/Informaciones farmaceuticas de la OMS, Vol. 2, No. 2, 1988)

p. 16 *delete/supprimer/suprimase* *insert/insérer/insértese*

levoglutamidum	**glutaminum**
levoglutamide	glutamine
lévoglutamide	glutamine
levoglutamida	glutamina

Recommended International Nonproprietary Names (Rec. INN): List 42
Dénominations communes internationales recommendées (DCI Rec.): Liste 42
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 42
(WHO Drug Information, Vol. 13, No. 3, 1999)

	suprimase	*insértese*
p. 184	carabersato	carabersat
p. 207	tonabersato	tonabersat

Recommended International Nonproprietary Names (Rec. INN): List 44
Dénominations communes internationales recommendées (DCI Rec.): Liste 44
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44
(WHO Drug Information, Vol. 14, No. 3, 2000)

p. 199 *delete/supprimer/suprimase* *insert/insérer/insértese*

nebostinelum	**neboglaminum**
nebostinel	neboglamine
nébostinel	néboglamine
nebostinel	neboglamina

p. 199 **onerceptum**

onercept	*replace the description by the following:* TNF-BP-(20-180)-peptide (part of extracellular domain of the glycosylated human Tumor Necrosis Factor Receptor 1)
onercept	*sustitúyase la descripción por la siguiente:* péptido (20-180) TNF-BP (parte del dominio extracelular del receptor 1 humano del factor de necrosis tumoral glicosilado)

Recommended International Nonproprietary Names (Rec. INN): List 45
Dénominations communes internationales recommendées (DCI Rec.): Liste 45
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 45
(WHO Drug Information, Vol. 15, No. 1, 2001)

p. 55 **evernimicinum**
evernimicina

sustitúyase la descripción por la siguiente:
O-3-*C*-metil-4-*O*-metil-3-nitro-2,3,6-tridesoxi-α-L-*arabino*-hexopiranosil-(1→3)-*O*-4-*O*-(3,5-dicloro-4-hidroxi-2-metoxi-6-metilbenzoil)-2,6-didesoxi-β-D-*arabino*-hexopiranosil-(1→4)-*O*-(1*R*)-2,6-didesoxi-D-*arabino*-hexopiranosilideno-(1→3-4)-*O*-3-*C*-metil-6-desoxi-β-D-manopiranosil-(1→3)-*O*-4-*O*-metil-6-desoxi-β-D-galactopiranosil-(1→4)-2,6-di-*O*-metil-β-D-manopiranosido de *O*-(1*R*)-4-*O*-(2,4-dihidroxi-6-metilbenzoil)-2,3-*O*-metileno-D-xilopiranosilideno-(1→3-4)-α-L-lixopiranosilo

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impaires des listes des DCIs proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.